← Back to all trials
Recruiting
NCT06855121
The Norwegian Immunotherapy in Multiple Myeloma Study
Conditions: Myeloma Multiple, Plasma Cell Leukemia, AL Amyloidosis
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 400
Sponsor: St. Olavs Hospital
Location: Sørlandet Hospital - Arendal Arendal
Summary
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
Eligibility Criteria
Inclusion criteria
* Participants age ≥ 18 years
* Prior diagnosis of one of the following
* Multiple myeloma as defined according to IMWG criteria
* Primary plasma cell leukemia as defined according to IMWG consensus definition
* AL-amyloidosis as defined according to IMWG criteria
* Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):
* Teclistamab (Tecvayli)
* Elranatamab (Elrexfio)
* Talquetamab (Talvey)
* Idecabtagene vicleucel (ide-cel/Abecma)
* Ciltacabtagene autoleucel (cilta-cel/Carvykti)
Exclusion Criteria:
* None
Source: ClinicalTrials.gov (NCT06855121). StuddyBuddy aggregates publicly available trial information.
